2nd Quarter - Report

TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Firm
Client
Income
—
Expenses
$840,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Corporate tax reform proposals including proposed board adjustment tax.

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA, has an interest in the issues listed above.

LobbyistCovered position, as disclosed
SUSIE AHN —
SHANNON DZUBIN —
DOLLY A JUDGE New —

Contacted: SENATE; White House Office; HOUSE OF REPRESENTATIVES

Health Issues HCR

HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

LobbyistCovered position, as disclosed
SUSIE AHN —
DEBRA BARRETT —
SHANNON DZUBIN —
ROBERT FALB —
DOLLY A JUDGE New —

Contacted: White House Office; SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 637 (115th), S. 771 (115th), H.R. 2051 (115th), H.R. 1628 (115th), H.R. 749 (115th), S. 469 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.